Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2016-08-24 Capital/Financing Update
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Appendix 3B 9 pages 465.7KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, specifically ordinary shares and employee options, by Mayne Pharma Group Limited. It includes detailed information about the class, number, terms, issue price, purpose, and quotation of the securities on the ASX (Australian Securities Exchange). The document is structured as a formal notification to the ASX about a capital raising event involving new share issuance and employee share options. There is no financial performance data, management discussion, or audit information present. The content aligns with announcements about capital structure changes and fundraising activities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the securities issued, confirming it is not merely a brief announcement or a report publication notice.
2016-08-24 English
Appendix 3B 9 pages 464.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new ordinary shares, terms of securities, issue price, purpose of the issue, and application for quotation on the ASX. The document includes sections on securities issued, quotation agreement, and employee options issued under an employee share option plan. There is no financial performance data, management discussion, or audit information. The document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares. This matches the definition of 'Share Issue/Capital Change' filings, which cover announcements regarding new share issues and capital changes. The document length is over 13,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2016-08-21 English
Response to ASX Appendix 3Y Query 3 pages 740.0KB
Director's Dealing Classification · 95% confidence The document is a letter from ASX Compliance Pty Limited to Mayne Pharma Group Limited regarding a late lodgement of an Appendix 3Y form, which is a Change of Director's Interest Notice. The letter discusses compliance with ASX listing rules 3.19A and 3.19B related to director disclosures of securities interests and the company's arrangements to ensure timely notification. The document is a regulatory inquiry and response about director share transactions and compliance with disclosure obligations, not a financial report or earnings release. It is focused on director dealings and compliance with listing rules, specifically about the late filing of a director's interest notice (Appendix 3Y). This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 7458 characters, sufficient to be a full letter rather than a brief announcement. Therefore, the appropriate classification is DIRS with high confidence.
2016-08-18 English
MYX announces acquisition of US foam dermatology assets 2 pages 137.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 August 2016 about Mayne Pharma acquiring rights to a portfolio of GSK foam dermatology products. It details the acquisition terms, product descriptions, strategic rationale, and expected financial impact. There are no financial statements, comprehensive financial performance data, or detailed management analysis typical of annual or interim reports. The document is a corporate announcement about a capital transaction (acquisition) involving assets and rights, which fits the category of Capital/Financing Update (CAP). The length is about 5,239 characters, consistent with an announcement rather than a full report. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2016-08-17 English
Investor Presentation Acquisition of GSK Foam Assets 10 pages 853.5KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about Mayne Pharma Group Limited's acquisition of foam dermatology product assets from GlaxoSmithKline (GSK). It includes extensive information about the transaction overview, strategic rationale, product descriptions, market data, and commercial execution plans. The content focuses on the acquisition details, product portfolios, market positioning, and future plans rather than financial statements or regulatory filings. There is no indication that this is a full annual or interim report, audit report, earnings release, or regulatory filing. It is a corporate announcement about a specific transaction (acquisition) with detailed strategic and product information. Therefore, the document fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions of assets.
2016-08-17 English
Change of Director's Interest Notice 2 pages 307.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including dates, number of shares acquired or disposed, and consideration amounts. The document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, management discussion, or other report content. The document length is 3447 characters, which is consistent with a detailed insider trading report rather than a full financial report or announcement. Therefore, this document fits the category of Director's Dealing (DIRS).
2016-08-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.